The Global Pharmaceutical Industry's Leading Forum for Guidance and Insight into the Complex Landscape of Early and Managed Access Programmes
The Pharmaceutical Industry continues to turn to Early and Managed Access Programmes (EMAPs) as the front line in fighting rare diseases and epidemic outbreaks. In many cases, critical patient or environmental conditions means that any delay in access can be fatal.
The Early and Managed Access Programmes Forum - The World's First and most Prestigious EMAP event - returns in October 2017, where industry leaders from Janssen, Bristol-Myers Squibb, Novartis, Incyte and Onconova will combine with Patient Advocacy Groups and Regulatory Experts from across Europe and the US, to address challenges at the heart of this vital field.
Patient demand for medication is only rising, with more Ophan and Rare diseases, and more pressure on the Pharmaceutical Industry to deliver patient treatments. There has never been a more important time to ensure that you understand the risks and challenges associated with Early or Managed Access Programs and are prepared for the ethical and regulatory pressures that come with these front-line medical developments and access programs.
The perfect environment to engage with Industry experts who have launched, managed and terminated EMAPs, this year’s event will see 20+ Industry Expert Speakers ready to help your team feel confident in addressing the regulatory, ethical and management aspects of your E/MAP and ensure you feel secure in your next steps.
2017 Speakers Included:
Head, Patient Support
Johnson and Johnson
Associate Director, Managed Access Programs, Ph IV & Medical Strategy
Head, Global Value, Access, & Pricing
Associate Consumer Lead
National Cancer Research Institute (NCRI)
Regulatory Operation Liaison, Europe
Arnold & Porter Kaye Scholer LLP
NexGen Healthcare Communications
FDA Life Sciences Partner
King & Spalding
Senior Legal Practitioner and Healthcare Ethics Lecturer
University College Cork
Pre-approval Access Consultant
TW Consulting Group
What is the industry saying about Pharma IQ's events?
"Extremely valuable"Policy Director, AstraZeneca, Delegate 2015
"My knowledge has increased, which I can take back to my organisation"Business Development, MultiPharma, Delegate 2015
"A valuable event providing lots of very useful information and relevant contacts" GMP/GDP Systems Manager, Intercept Pharmaceuticals, Delegate 2015
"Good event, good networking opportunities and relationship building." Regulatory Affairs Manager, Idis, Delegate 2015